News
Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434 in MSA – MELBOURNE, Australia and SAN FRANCISCO, (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback